Printer Friendly

TSI AND CYTOTHERAPEUTICS TO JOINTLY PROVIDE ADVANCED RESEARCH TESTING SERVICE FOR RAPID AND EARLY EVALUATION OF BIOPHARMACEUTICAL PRODUCTS

TSI AND CYTOTHERAPEUTICS TO JOINTLY PROVIDE ADVANCED RESEARCH TESTING SERVICE FOR RAPID AND EARLY EVALUATION OF BIOPHARMACEUTICAL PRODUCTS
 WORCESTER, Mass., Jan. 13 /PRNewswire/ -- TSI Corporation (NASDAQ: TSIN) and CytoTherapeutics, Inc. (formerly Cellular Transplants, Inc.) today announced that the companies have signed an agreement to jointly provide an advanced research testing system to pharmaceutical and biotechnology companies. The system, which is based on membrane encapsulated living cells, should allow for the rapid and early evaluation of biopharmaceutical products in laboratory animals. The major advantage of the system is that it eliminates the need to conduct time-consuming and costly scale-up and process development activities before the therapeutic potential of the molecule is established.
 The research testing service combines the complementary expertise of the two companies. CytoTherapeutics will use its CRIB(TM) (Cellular Replacement by Immunoisolatory Biocapsule) membrane system to encapsulate the client's cell line and TSI will perform pharmacology and drug interaction studies. TSI will begin marketing the service next month.
 "Our new testing service has potential to accelerate the drug development process," commented James P. Sherblom, chairman and chief executive officer of TSI. "CytoTherapeutics' cell encapsulation technology represents an innovation in research testing. The service should provide our customers with a rapid and less costly alternative to the scale-up and process development activities traditionally required to assess therapeutic activity."
 "We are extremely pleased to be working with TSI, a recognized leader in providing advanced testing services to the pharmaceutical and biotechnology industries," said Seth Rudnick, M.D., CytoTherapeutics president and chief executive officer. "This venture represents a significant endorsement of our proprietary cell encapsulation technology and a unique opportunity for CytoTherapeutics to generate revenues near- term as the company continues development of encapsulated therapies for Parkinson's disease and diabetes."
 In the CRIB(TM) system, living cells are encapsulated in a selectively permeable membrane capsule that when implanted in a host, renders the cells "invisible" to the immune system. At the same time, the membrane allows nutrients from the body to reach the cells and allows therapeutic molecules produced by them to be secreted into the body. CytoTherapeutics has established that the cells remain viable in the capsule when implanted in animal models and that the therapeutic molecules produced by the cells can have the desired biological effects.
 CytoTherapeutics, Inc. is developing patentable membrane products to treat a variety of chronic and disabling diseases through the implantation of encapsulated living cells and tissues. These encapsulated living cells, protected from the body's immune system by the membrane, have the potential to replace a wide range of missing or deficient proteins, neurotransmitters, or other molecules critical to health. CytoTherapeutics' initial products, based on the company's proprietary CRIB(TM) membrane technology, are targeted for the treatment of Parkinson's disease and Type I diabetes. The company is based in Providence, R.I.
 TSI is a life sciences company offering in vitro and in vivo preclinical and toxicology testing services, human clinical testing services, and diagnostic intermediate products. TSI is also developing advanced toxicology tests and disease models based on genetic engineering and transgenic techniques to improve the efficiency of the pharmaceutical/chemical development process.
 -0- 1/13/92
 /CONTACT: Lynne H. Brum of Feinstein Partners, 617-577-8110, for TSI, or Nunro Pitt, senior vp of TSI, 508-755-0550, or Erika Karplus of CytoTherapeutics, 401-272-3310/
 (TSIN) CO: TSI Corporation; CytoTherapeutics, Inc. ST: Massachusetts, Rhode Island IN: MTC SU: PDT


LJ-KA -- NE009 -- 8995 01/13/92 10:13 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 13, 1992
Words:569
Previous Article:MID AM, INC. SETS QUARTERLY EARNINGS RECORD
Next Article:BP STEPS UP APPRAISAL OF COLOMBIAN FIELD
Topics:


Related Articles
TSI ANNOUNCES Q2 OUTLOOK AND MANAGEMENT APPOINTMENTS
TSI CORPORATION REPORTS RECORD FIRST HALF AND SECOND QUARTER REVENUES
TSI ANNOUNCES CONVERTIBILITY OF PREFERRED STOCK
TSI CORPORATION ANNOUNCES PROPOSED ACQUISITION OF GERMAN PRECLINICAL TESTING FACILITY
TSI CORPORATION REPORTS NINE-MONTH AND THIRD QUARTER RESULTS
TSI COMPLETES ACQUISITION OF HSRI
TSI CORPORATION TO ACQUIRE CLINICAL RESEARCH GROUP
TSI CORP. ANNOUNCES RESTRUCTURING AND FORECASTS YEAR-END RESULTS
TSI CORPORATION REPORTS RECORD FIRST QUARTER REVENUES
TSI CORPORATION ANNOUNCES MANAGEMENT APPOINTMENTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters